Gibbs Michael Terrence 4
4 · T2 Biosystems, Inc. · Filed Mar 9, 2023
Insider Transaction Report
Form 4
Gibbs Michael Terrence
General Counsel
Transactions
- Sale
Common Stock
2023-02-28$0.59/sh−1,585$935→ 6,517 total - Sale
Common Stock
2023-02-22$0.65/sh−2,145$1,394→ 5,188 total - Exercise/Conversion
Common Stock
2023-02-24+2,914→ 8,102 total - Exercise/Conversion
Restricted Stock Units
2023-02-24−2,914→ 2,914 total→ Common Stock (2,914 underlying) - Exercise/Conversion
Common Stock
2023-02-20+4,000→ 7,333 total - Exercise/Conversion
Restricted Stock Units
2023-02-20−4,000→ 8,000 total→ Common Stock (4,000 underlying)
Footnotes (4)
- [F1]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- [F2]The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2018.
- [F3]On February 20, 2022 the reporting person was granted 12,000 RSU's that vest in three equal annual installments commencing on February 20, 2023
- [F4]On February 24, 2021 the reporting person was granted 8,743 RSU's that vest in three equal annual installments commencing on February 24, 2022.